Literature DB >> 16234301

Emerging treatment strategies for adrenocortical carcinoma: a new hope.

Lawrence S Kirschner1.   

Abstract

CONTEXT: Adrenocortical carcinoma (ACC) is a rare cancer but one that has devastating consequences for affected patients. Surgery is the mainstay of therapy, although the high frequency of metastatic disease implies that it is frequently noncurative. Traditional cytotoxic chemotherapy for ACC has generally produced disappointing responses, implying the need for the new therapies for this disease. EVIDENCE ACQUISITION: Review articles and primary literature were identified by extensive PubMed searching to obtain papers evaluating the current state of knowledge regarding ACC, as well as assessing the development of new therapeutic modalities for the treatment of cancer. When needed, additional articles were identified from the reference lists of the papers obtained from the primary screen. EVIDENCE SYNTHESIS: Multiple new modalities that may enhance the future treatment of ACC were identified. They include the following: combating drug resistance, targeting tumor vasculature, inhibiting signaling pathways with small molecules, and using gene and/or immunotherapy. This review provides a brief summary of the progress and prospects of each of these modalities and focuses on emerging data and treatments that may alter the course of this disease within the next few years.
CONCLUSIONS: Despite the current grim outlook, the recent applications of emerging technology to the study of ACC and the development of newer, "targeted" therapies for cancer suggest the possibility of a new hope for patients with this disease, although these therapies will need to be evaluated by rigorous clinical trials to verify their effectiveness.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16234301     DOI: 10.1210/jc.2005-1739

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  16 in total

Review 1.  Review paper: origin and molecular pathology of adrenocortical neoplasms.

Authors:  M Bielinska; H Parviainen; S Kiiveri; M Heikinheimo; D B Wilson
Journal:  Vet Pathol       Date:  2009-03       Impact factor: 2.221

2.  Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and β-catenin.

Authors:  Joanne H Heaton; Michelle A Wood; Alex C Kim; Lorena O Lima; Ferdous M Barlaskar; Madson Q Almeida; Maria C B V Fragoso; Rork Kuick; Antonio M Lerario; Derek P Simon; Ibere C Soares; Elisabeth Starnes; Dafydd G Thomas; Ana C Latronico; Thomas J Giordano; Gary D Hammer
Journal:  Am J Pathol       Date:  2012-07-15       Impact factor: 4.307

Review 3.  Current and emerging therapies for advanced adrenocortical carcinoma.

Authors:  Lyndal J Tacon; Ruth S Prichard; Patsy S H Soon; Bruce G Robinson; Roderick J Clifton-Bligh; Stan B Sidhu
Journal:  Oncologist       Date:  2011-01-06

Review 4.  Diagnosis and management of adrenal cortical carcinoma.

Authors:  Brant R Fulmer
Journal:  Curr Urol Rep       Date:  2007-01       Impact factor: 3.092

5.  Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.

Authors:  Ferdous M Barlaskar; Aaron C Spalding; Joanne H Heaton; Rork Kuick; Alex C Kim; Dafydd G Thomas; Thomas J Giordano; Edgar Ben-Josef; Gary D Hammer
Journal:  J Clin Endocrinol Metab       Date:  2008-10-14       Impact factor: 5.958

Review 6.  [Adrenocortical carcinoma. Diagnostic work-up and treatment].

Authors:  S Johanssen; M Fassnacht; D Brix; A-C Koschker; S Hahner; H Riedmiller; B Allolio
Journal:  Urologe A       Date:  2008-02       Impact factor: 0.639

7.  Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma.

Authors:  Paul Haluska; Frank Worden; David Olmos; Donghua Yin; David Schteingart; Gretchen N Batzel; M Luisa Paccagnella; Johann S de Bono; Antonio Gualberto; Gary D Hammer
Journal:  Cancer Chemother Pharmacol       Date:  2009-08-02       Impact factor: 3.333

8.  Current and emerging therapeutic options in adrenocortical cancer treatment.

Authors:  Antonio Stigliano; Lidia Cerquetti; Camilla Sampaoli; Barbara Bucci; Vincenzo Toscano
Journal:  J Oncol       Date:  2012-08-14       Impact factor: 4.375

9.  Adrenocortical oncocytic carcinoma with recurrent metastases: a case report and review of the literature.

Authors:  Pinelopi Argyriou; Charalambos Zisis; Nektarios Alevizopoulos; Emmanuel M Kefaloyannis; Constantine Gennatas; Constantina D Petraki
Journal:  World J Surg Oncol       Date:  2008-12-17       Impact factor: 2.754

10.  Differential Expression Profiles of Cell-to-Matrix-Related Molecules in Adrenal Cortical Tumors: Diagnostic and Prognostic Implications.

Authors:  Marco Volante; Ida Rapa; Jasna Metovic; Francesca Napoli; Cristian Tampieri; Eleonora Duregon; Massimo Terzolo; Mauro Papotti
Journal:  J Pers Med       Date:  2021-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.